Lee M, Lofgren KT, Thomas A, et al. - Given the controversies and unresolved questions in reproductive medicine regarding the utility of preimplantation genetic testing for aneuploidy (PGT-A) as an adjunct to in vitro fertilization (IVF), researchers herein examined the cost-effectiveness of PGT-A for the treatment of infertility in the United States. They analyzed 114,157 first fresh IVF stimulations and 44,508 linked frozen embryo transfer cycles occurring between 2014 and 2016 in the United States, as reported to the Society for Assisted Reproductive Technology Clinic Outcomes Reporting System, a national data registry. Findings suggest that patient age and perspective influence the cost-effectiveness of PGT-A. At age 35 and older, PGT-A resulted in more cumulative births, but was linked with higher costs from both perspectives. From a patient perspective, the no PGT-A strategy was favored by the incremental cost per live birth from < 35 until age 38, and PGT-A was favored beginning at age 39. From an economic perspective, they emphasize no universal implementation of routine PGT-A, but it may be cost-effective in certain scenarios.